Long-Term Safety and Clinical Outcomes with Insulin Degludec/Insulin Aspart Treatment in Japanese Patients with Diabetes: A Real-World, Prospective, Observational Study

What Was Tested

Researchers studied Insulin Aspart in this observational study publication.

This post-marketing surveillance study assessed long-term safety and clinical outcomes with IDegAsp in a Japanese real-world setting.

Who Took Part

Multicentre, prospective, observational, open-label, single-arm study of Japanese patients with diabetes requiring insulin therapy, who had switched to IDegAsp at their treating physician's discretion in clinical practice.

How the Study Was Run

The researchers set it up as a randomized, open-label and multicenter study.

Because people in this Insulin Aspart study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Being open-label, the Insulin Aspart study did not mask who received what.

Running at several centres spread the Insulin Aspart study over different clinics and patient groups.

One year after initiating IDegAsp, incidence of adverse events (AEs [primary endpoint]), serious AEs, adverse drug reactions (ADRs), and severe hypoglycaemia (secondary safety endpoints) were assessed in the safety analysis set (SAS).

What Was Measured

This post-marketing surveillance study assessed long-term safety and clinical outcomes with IDegAsp in a Japanese real-world setting.

PubMed files the paper under topics including Blood Glucose, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Hypoglycemic Agents, Insulin Aspart, Insulin, Long-Acting and Japan.

The authors tagged it with the keywords HbA1c, IDegAsp and Safety.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Insulin Aspart.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2022 (Advances in therapy), a journal based in United States.

More context: the Insulin Aspart compound page, all human trials.